| 101 |
15160934 | The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia. | 2004 Apr |
4 |
| 102 |
15461930 | Arsenic trioxide liposomes: encapsulation efficiency and in vitro stability. | 2004 |
2 |
| 103 |
12667397 | Nuclear matrix associated protein PML: an arsenic trioxide apoptosis therapeutic target protein in HepG2 cells. | 2003 Jan |
1 |
| 104 |
12795834 | [Mechanism of arsenic trioxide-induced apoptosis in hepatic blastoma cells HepG2]. | 2003 Mar |
4 |
| 105 |
12895391 | Monitoring PML-RARalpha in acute promyelocytic leukemia. | 2003 Sep |
1 |
| 106 |
12915590 | Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. | 2003 Oct 1 |
1 |
| 107 |
14534537 | Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis. | 2003 Oct 9 |
5 |
| 108 |
14668793 | Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1. | 2003 Dec 11 |
2 |
| 109 |
14706140 | [Improved RT-PCR for detection of PML/RARalpha fusion gene in rapid diagnosis of acute promyelocytic leukemia]. | 2003 Dec |
1 |
| 110 |
11890109 | Mechanism of action of all-trans retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia. | 2002 Feb |
1 |
| 111 |
12429934 | Arsenic trioxide arrests cells early in mitosis leading to apoptosis. | 2002 May-Jun |
1 |
| 112 |
11133770 | Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. | 2001 Jan 1 |
2 |
| 113 |
11172537 | Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. | 2001 Jan |
3 |
| 114 |
11413191 | Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. | 2001 Jun 18 |
10 |
| 115 |
11704843 | Arsenic trioxide, a therapeutic agent for APL. | 2001 Oct 29 |
1 |
| 116 |
11704854 | Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. | 2001 Oct 29 |
1 |
| 117 |
11779431 | Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells. | 2001 Jan |
1 |
| 118 |
10830735 | Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy. | 2000 Jul |
2 |
| 119 |
10910048 | BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. | 2000 Jul 1 |
2 |
| 120 |
11798775 | [Effects of arsenic trioxide on K562 cells stably expressing two promyelocytic leukemia-specific fusion proteins]. | 2000 Apr |
2 |
| 121 |
10023688 | Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. | 1999 Jan 28 |
1 |
| 122 |
10328107 | Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. | 1999 May 5 |
2 |
| 123 |
10373566 | PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. | 1999 Jul |
3 |
| 124 |
11721366 | [Effects of As2O3 on the BCR/ABL protein tyrosine phosphorylation in K562 cells]. | 1999 Dec |
1 |
| 125 |
9427741 | Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. | 1998 Jan 2 |
2 |
| 126 |
9450572 | Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. | 1998 Jan 21 |
1 |
| 127 |
9596679 | Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. | 1998 Jun 1 |
4 |
| 128 |
9716575 | Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. | 1998 Sep 1 |
11 |
| 129 |
9834237 | Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. | 1998 Dec 1 |
2 |
| 130 |
9129042 | Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. | 1997 May 1 |
4 |
| 131 |
9535176 | Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. | 1997 Oct-Dec |
2 |
| 132 |
9772451 | [Double effects of arsenic trioxide (As2O3) on acute promyelocytic leukemic cell line]. | 1997 Jul |
4 |
| 133 |
15622748 | [Effects of arsenic trioxide on the subcellular localization of PML/PML-RARalpha protein in leukemic cells]. | 1997 Jan |
6 |
| 134 |
8704214 | In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. | 1996 Aug 1 |
8 |
| 135 |
8986606 | The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic. | 1996 Dec 15 |
1 |